VEGFA and hypertensive disorder: Despite Interaction tests for grade 3/4 anti-VEGF-related did not suggest either evidence of heterogeneity (p > 0.1), the incidence of grade 3/4 anti-VEGF-related toxicities such as hypertension, venous thromboembolic events and proteinuria were, as expected, augmented by aflibercept.